Cargando…
Why rheumatologic skin disease?
Autores principales: | Sontheimer, Richard D., Connolly, M. Kari, Fiorentino, David F., Werth, Victoria P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8033298/ https://www.ncbi.nlm.nih.gov/pubmed/33842649 http://dx.doi.org/10.21037/atm-2020-rsd-14 |
Ejemplares similares
-
AB014. Developing classification criteria for skin-predominant dermatomyositis: assessing the methodology of the prospective validation study
por: Concha, Josef Symon S., et al.
Publicado: (2021) -
AB021. Comparing the performance of two interferon-gamma release assays in autoimmune skin disease patients: a prospective study
por: Krain, Rebecca L., et al.
Publicado: (2021) -
AB015. Skin disease activity and autoantibody phenotype are major determinants of blood interferon signatures in dermatomyositis
por: Tabata, Mika, et al.
Publicado: (2021) -
AB004. Evaluating differences in meaningful change in disease activity between different races and clinical subtypes affected by cutaneous lupus erythematosus
por: Chakka, Srita, et al.
Publicado: (2021) -
The CLASI, a validated tool for the evaluation of skin disease in lupus erythematosus: a narrative review
por: Chakka, Srita, et al.
Publicado: (2021)